Ionis Additional Paid In Capital from 2010 to 2024
| IONS Stock | USD 35.90 0.53 1.50% |
Additional Paid In Capital | First Reported 2010-06-30 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 312.9 M |
Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.6 M, Interest Expense of 85.5 M or Total Revenue of 827 M, as well as many indicators such as Price To Sales Ratio of 15.6, Dividend Yield of 0.0 or PTB Ratio of 17.8. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
Ionis | Additional Paid In Capital |
Latest Ionis Pharmaceuticals' Additional Paid In Capital Growth Pattern
Below is the plot of the Additional Paid In Capital of Ionis Pharmaceuticals over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on Ionis Pharmaceuticals Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Ionis Pharmaceuticals Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Ionis Pharmaceuticals shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. Ionis Pharmaceuticals' Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Additional Paid In Capital | 10 Years Trend |
|
Additional Paid In Capital |
| Timeline |
Ionis Additional Paid In Capital Regression Statistics
| Arithmetic Mean | 816,806,050 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 85.07 | |
| Mean Deviation | 653,444,840 | |
| Median | 1,309,107,000 | |
| Standard Deviation | 694,854,337 | |
| Sample Variance | 482822.6T | |
| Range | 1.6B | |
| R-Value | 0.88 | |
| Mean Square Error | 114369.1T | |
| R-Squared | 0.78 | |
| Significance | 0.000013 | |
| Slope | 137,226,576 | |
| Total Sum of Squares | 6759515.7T |
Ionis Additional Paid In Capital History
About Ionis Pharmaceuticals Financial Statements
Ionis Pharmaceuticals shareholders use historical fundamental indicators, such as Additional Paid In Capital, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Ionis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Ionis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Additional Paid In Capital | 1.5 B | 1.6 B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.